XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
R
R

Regeneron

News

Reuters - 2 days ago

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug

China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug Nov 20 (Reuters) - Eli Lilly LLY.N and Hong Kong-listed Laekna 2105.HK will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on Wednesday. WHY IT MATTERS Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion in revenue by the next decade.
R
Reuters - 1 week ago

Dupixent SBLA Accepted For FDA Review For Treatment Of Chronic Spontaneous Urticaria

BRIEF-Dupixent SBLA Accepted For FDA Review For Treatment Of Chronic Spontaneous Urticaria Nov 15 (Reuters) - Sanofi SA SASY.PA : PRESS RELEASE: DUPIXENT SBLA ACCEPTED FOR FDA REVIEW FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA FDA DECISION ON DUPIXENT EXPECTED BY APRIL 18, 2025 SAFETY RESULTS IN ALL LIBERTY-CUPID PHASE 3 STUDIES WERE GENERAL
R
S
Reuters - 1 week ago

Regeneron To Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types Of Blood Cancers And Disorders At ASH

BRIEF-Regeneron To Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types Of Blood Cancers And Disorders At ASH Nov 13 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON TO HIGHLIGHT PIONEERING PIPELINE PROGRESS ACROSS MULTIPLE MODALITIES SPANNING 10 TYPES OF BLOOD CANCERS AND DISORDERS AT ASH Source text: nGN
R
Reuters - 3 weeks ago

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
A
C
E
I
K
R
A
A
E
G
U
A
A
A
I
Reuters - 3 weeks ago

U.S. Amazon, IQVIA Holdings, Uber

U.S. RESEARCH ROUNDUP-Amazon, IQVIA Holdings, Uber Nov 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Amazon, IQVIA Holdings and Uber, on Friday. HIGHLIGHTS * Amazon AMZN.O : JP Morgan raises target price to $250 from $230 * Cheniere Energy Inc LNG.N : Raymond James raises target price to $225 from $210 * IQVIA Holdings Inc IQV.N : TD Cowen cuts target price to $255 from $270 * Regeneron Pharmaceuticals Inc REGN.O
A
C
E
I
K
R
U
A
A
S
E
G
U
I
Reuters - 3 weeks ago

Regeneron Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary

Regeneron Pharmaceuticals Inc reports results for the quarter ended in January 1 - Earnings Summary Regeneron Pharmaceuticals Inc REGN.OQ reported quarterly adjusted earnings of $12.46​​ per share for the quarter ended January 1, higher than the same quarter last year, when the company reported EPS of $11.59. The mean expectation of twenty four analysts for the quarter was for earnings of $11.69 per share.
R
Reuters - 3 weeks ago

Regeneron Pharmaceuticals Files For Mixed Shelf

BRIEF-Regeneron Pharmaceuticals Files For Mixed Shelf Oct 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PHARMACEUTICALS INC FILES FOR MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: [ID:n0001104659-24-113087] Further company coverage: REGN.O
R
Reuters - 3 weeks ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Xcel Energy Inc XEL.OQ +6.1% Booking Holdings Inc BKNG.OQ +4.7% Warner Bros Discovery Inc WBD.OQ +4.5% Comcast Corp CMCSA.OQ +3.1% Dollar Tree Inc DLTR.OQ +2.5% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -12.2% Regeneron Pharmaceuticals Inc REGN.OQ -9.8% IDEXX Laboratories Inc IDXX.OQ -8.9% Arm Holdings PLC ARM.OQ -8.4% Microsoft Corp MSFT.OQ -5.1% The Nasda
C
I
M
R
X
D
U
B
Reuters - 3 weeks ago

U.S. STOCKS Estee Lauder, DoorDash, Peloton Interactive

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, DoorDash, Peloton Interactive Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Thursday, as warnings from Microsoft and Meta Platforms about soaring AI costs dampened enthusiasm for megacap stocks, which have led the market this year.
A
B
C
C
E
I
M
R
W
X
S
U
U
E
E
P
U
H
I
T
Reuters - 3 weeks ago

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Xcel Energy Inc XEL.OQ +6.8% Warner Bros Discovery Inc WBD.OQ +6.8% Booking Holdings Inc BKNG.OQ +5.3% Comcast Corp CMCSA.OQ +2.9% Cognizant Technology Solutions Corp CTSH.OQ +2.8% Bottom Performers Percent Change Super Micro Computer Inc SMCI.OQ -14.7% Regeneron Pharmaceuticals Inc REGN.OQ -9.6% IDEXX Laboratories Inc IDXX.OQ -9.0% Arm Holdings PLC ARM.OQ -8.5% Microsoft Corp MSF
C
C
I
M
R
X
U
B
Reuters - 3 weeks ago

Regeneron falls as higher dose version of eye drug misses sales expectations

BUZZ-Regeneron falls as higher dose version of eye drug misses sales expectations Updates ** Shares of drugmaker Regeneron Pharmaceuticals REGN.O fall 9.6% to $834.12, its lowest since December last year ** Regeneron reports Q3 sales of $392 million for the higher dose version of its eye drug Eylea, missing analysts' expectation for the second stra
R
Reuters - 3 weeks ago

Regeneron shares drop as higher-dose Eylea drug misses sales estimates

UPDATE 1-Regeneron shares drop as higher-dose Eylea drug misses sales estimates Rewrites throughout to add details on higher dose version of Eylea By Christy Santhosh Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O o n Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%.
B
R
R
S
Reuters - 3 weeks ago

Regeneron falls as higher dose version of eye drug misses sales expectations

BUZZ-Regeneron falls as higher dose version of eye drug misses sales expectations ** Shares of drugmaker Regeneron Pharmaceuticals REGN.O fall 1.9% to $904.99 premarket ** Regeneron reports Q3 sales of $392 million for the higher dose version of its eye drug Eylea, missing analysts' expectation of $417 million - LSEG data ** Co is trying upgrade pa
R
Reuters - 3 weeks ago

Regeneron beats results estimates on demand for eczema treatment, eye drug

Regeneron beats results estimates on demand for eczema treatment, eye drug Oct 31 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals REGN.O beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven by strong demand for its eczema treatment Dupixent and blockbuster eye disease drug Eylea. Regeneron has been looking to upgrade patients who use Eylea to a high-dose version, as the drug that has long been its cash cow faces the threat of biosimilar products and stiff comp
B
R
R
S
Reuters - 3 weeks ago

Regeneron Reports Third Quarter 2024 Financial AND OPERATING RESULTS

BRIEF-Regeneron Reports Third Quarter 2024 Financial AND OPERATING RESULTS Oct 31 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS REGENERON PHARMACEUTICALS: QTRLY U.S. NET SALES FOR EYLEA HD & EYLEA INCREASED 3% VERSUS Q3 2023 TO $1.54 BILLION REGENERON PHARMACEUTICALS: QTRLY D
R
Reuters - 3 weeks ago

Regeneron Q3 Adjusted EPS USD 12.46 Vs. IBES Estimate USD 11.7

BRIEF-Regeneron Q3 Adjusted EPS USD 12.46 Vs. IBES Estimate USD 11.7 Oct 31 (Reuters) - Regeneron Q3 revenue USD 3,720 million vs. IBES estimate USD 3,670 million. Q3 EPS USD 11.54 outlook FY capex USD 700-740 million
R
Reuters - 3 weeks ago

Megacaps spooked, world bonds on edge

MORNING BID AMERICAS-Megacaps spooked, world bonds on edge A look at the day ahead in U.S. and global markets from Mike Dolan Cloudy outlooks from U.S. megacaps Microsoft and Meta combined with edgy government bond markets around the world to unsettle investors on Thursday, with the latest U.S. opinion polls showing next week's presidential election is no foregone conclusion.
A
A
C
E
I
M
M
R
U
U
X
A
J
U
U
U
U
E
E
I
W
B
E
H
Reuters - 3 weeks ago

What to Watch in the Day Ahead - Thursday, October 31

What to Watch in the Day Ahead - Thursday, October 31 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT Analysts expect Apple to report a 5.5% growth in quarterly revenue for its fourth fiscal quarter.
A
A
C
I
I
R
E
U
Reuters - 4 weeks ago

What to Watch in the Week Ahead and on Monday, October 28

What to Watch in the Week Ahead and on Monday, October 28 The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US . Thomson One users can register at RT/DAY/US. All times in ET/GMT ON MONDAY Ford is expected to report higher third-quarter revenue and profit, aided by sales of its commercial vehicles.
A
A
B
C
C
C
C
D
G
I
J
M
P
P
R
S
K
K
E
R
U
Reuters - 4 weeks ago

U.S. Coca-Cola, Nextera Energy Partners, ServiceNow

U.S. RESEARCH ROUNDUP-Coca-Cola, Nextera Energy Partners, ServiceNow Oct 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Coca-Cola, Nextera Energy Partners, and ServiceNow on Thursday. HIGHLIGHTS * Avery Dennison Corp AVY.N : JP Morgan cuts to neutral from overweight * Coca-Cola Co KO.N : JP Morgan cuts target price to $75 from $78 * Nextera Energy Partners LP NEP.N : JP Morgan raises to neutral from underweight *
A
A
A
B
C
D
D
E
E
N
R
C
L
T
E
E
I
S
T
A
A
E
E
G
H
L
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.